Clinical

Trials

Harnessing The Power Of Science For Patient Benefit

By embracing challenging experiments and asking difficult questions, we act with urgency to discover and develop medicines that will have a meaningful impact on patients. Designed with clinically relevant endpoints and predefined benchmarks for success, our trials are designed to promote efficient decisions to accelerate a program when promising data emerges.
clinical-trials-export
Image of Circles

Our Clinical Trials

Asset/Study

CLN-619
A Phase 1, open-label, multicenter study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.

Design

A study investigating the safety, efficacy, PK, and PD activity.

Status
 
Recruiting
Study ID
NCT05117476
Asset/Study

Zipalertinib (CLN-081/TAS6417)
The REZILIENT 1 Trial, a Phase 1/2a, Open-label, multicenter, first-in-human trial in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations.

Design

Evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy

Status
 
Recruiting
Study ID

NCT04036682

Asset/Study

CLN-049
A Phase 1, open-label, multicenter, first-in-human study of CLN-049 in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Design

A study investigating the safety, tolerability, PK, PD, and preliminary efficacy.

Status
 
Recruiting
Study ID
NCT05143996
Asset/Study
CLN-418 (HBM7008) A Phase 1, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CLN-418 (HBM7008), and to determine the maximum tolerated dose and/or recommended Phase 2 study dose in patients with advanced solid tumors.
Design
A Phase 1 monotherapy dose escalation/expansion study.
Status
 
Recruiting
Study ID

NCT05306444

Asset/Study

CLN-617

A Phase 1 multi-center, open-label study to evaluate the safety and efficacy of CLN-617 alone and in combination with pembrolizumab in patients with advanced solid tumors (NCT06035744).

Design

A study investigating the safety, efficacy, PK, and PD activity.

Status
 
Recruiting
Study ID

NCT06035744